Bausch Health Companies Inc.
BHC.TOTSXHealthcare● Active
$7.49
+$0.18(+2.46%)
Market Cap$2.8B
P/E Ratio—
52W High$11.97
52W Low$6.29
Bausch Health Companies Inc. (BHC.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BHC.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$1.06
Est. $0.92 · +15.2%
Revenue
$3.44B
Est. $3.29B · +4.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
BHC.TO reports quarterly as a TSX-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | $1.39 | — | — | — | $3.62B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | $0.92 | $1.06 | +15.2% | $3.44B | $3.29B | +4.3% |
| ▼ Q1 FY2026 | Feb 18, 2026 | $1.67 | $1.47 | -12.0% | $3.83B | $3.75B | +2.1% |
| ▼ Q3 FY2025 | Jul 30, 2025 | $1.16 | $0.56 | -52.1% | $3.45B | $2.58B | +33.4% |
| ▼ Q2 FY2025 | Apr 30, 2025 | $0.79 | $0.60 | -24.1% | $3.22B | $2.28B | +41.3% |
| ▼ Q1 FY2025 | Feb 20, 2025 | $1.19 | $1.15 | -3.4% | $3.68B | $2.29B | +60.9% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $1.06 | $1.13 | +6.6% | $3.41B | $2.52B | +35.3% |
| ▼ Q3 FY2024 | Aug 1, 2024 | $0.88 | $0.04 | -95.8% | $3.29B | $3.22B | +2.1% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
$1.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
$1.06
EPS Est.
$0.92
EPS Surpr.
+15.2%
Revenue
$3.44B
Q1 FY2026
Feb 18, 2026Miss
EPS Actual
$1.47
EPS Est.
$1.67
EPS Surpr.
-12.0%
Revenue
$3.83B
Q3 FY2025
Jul 30, 2025Miss
EPS Actual
$0.56
EPS Est.
$1.16
EPS Surpr.
-52.1%
Revenue
$3.45B
Q2 FY2025
Apr 30, 2025Miss
EPS Actual
$0.60
EPS Est.
$0.79
EPS Surpr.
-24.1%
Revenue
$3.22B
Q1 FY2025
Feb 20, 2025Miss
EPS Actual
$1.15
EPS Est.
$1.19
EPS Surpr.
-3.4%
Revenue
$3.68B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$1.13
EPS Est.
$1.06
EPS Surpr.
+6.6%
Revenue
$3.41B
Q3 FY2024
Aug 1, 2024Miss
EPS Actual
$0.04
EPS Est.
$0.88
EPS Surpr.
-95.8%
Revenue
$3.29B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.17 | $1.19 | $1.23 | 2 |
| Q3 FY2027 | $1.06 | $1.08 | $1.10 | 2 |
| Q2 FY2027 | $0.89 | $0.90 | $0.93 | 2 |
| Q1 FY2027 | $0.73 | $0.74 | $0.76 | 3 |
| Q4 FY2026 | $1.30 | $1.32 | $1.35 | 3 |
| Q3 FY2026 | $1.02 | $1.24 | $1.51 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.7B | $2.8B | $2.8B | 2 |
| Q3 FY2027 | $2.6B | $2.7B | $2.7B | 2 |
| Q2 FY2027 | $2.6B | $2.6B | $2.6B | 2 |
| Q1 FY2027 | $2.4B | $2.4B | $2.5B | 2 |
| Q4 FY2026 | $2.7B | $2.8B | $2.8B | 2 |
| Q3 FY2026 | $2.7B | $2.7B | $2.7B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +15.2% | $7.77 | $7.66 | -1.42% |
| ▼ Q1 FY2026 | Feb 18, 2026 | -12.0% | $8.17 | $8.51 | +4.16% |
| ▼ Q3 FY2025 | Jul 30, 2025 | -52.1% | $9.41 | $8.85 | -5.95% |
| ▼ Q2 FY2025 | Apr 30, 2025 | -24.1% | $7.60 | $7.33 | -3.55% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -3.4% | $9.30 | $10.18 | +9.46% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +6.6% | $11.36 | $11.37 | +0.09% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -95.8% | $8.32 | $8.47 | +1.80% |
| ▼ Q2 FY2024 | May 2, 2024 | -16.7% | $12.03 | $11.05 | -8.15% |
Q2 FY2026-1.42%
Report Date
Apr 29, 2026
EPS Beat/Miss
+15.2%
Price Before
$7.77
Price After
$7.66
Q1 FY2026+4.16%
Report Date
Feb 18, 2026
EPS Beat/Miss
-12.0%
Price Before
$8.17
Price After
$8.51
Q3 FY2025-5.95%
Report Date
Jul 30, 2025
EPS Beat/Miss
-52.1%
Price Before
$9.41
Price After
$8.85
Q2 FY2025-3.55%
Report Date
Apr 30, 2025
EPS Beat/Miss
-24.1%
Price Before
$7.60
Price After
$7.33
Q1 FY2025+9.46%
Report Date
Feb 20, 2025
EPS Beat/Miss
-3.4%
Price Before
$9.30
Price After
$10.18
Q4 FY2024+0.09%
Report Date
Oct 30, 2024
EPS Beat/Miss
+6.6%
Price Before
$11.36
Price After
$11.37
Q3 FY2024+1.80%
Report Date
Aug 1, 2024
EPS Beat/Miss
-95.8%
Price Before
$8.32
Price After
$8.47
Q2 FY2024-8.15%
Report Date
May 2, 2024
EPS Beat/Miss
-16.7%
Price Before
$12.03
Price After
$11.05
Avg Beat Reaction-0.66%
Avg Miss Reaction-0.37%
Beat Rate2 / 8 quarters
Largest Move+9.46% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BHC.TO ends December
Bausch Health Companies Inc. (BHC.TO) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $1.06 — beating the analyst consensus of $0.92 by +15.2%. The next BHC.TO earnings date is expected around September 1, 2026.
Each quarter, investors track BHC.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BHC.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BHC.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BHC.TO earnings · 5 questionsBausch Health Companies Inc.'s next earnings report is expected around September 1, 2026. BHC.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BHC.TO historically reports after market close (AMC).
BHC.TO earnings datewhen is BHC.TO earningsBHC.TO next earnings datewhen does BHC.TO report earningsBHC.TO earnings calendar
▸ Source: FMP · Bausch Health Companies Inc. SEC filings · US GAAP · Bausch Health Companies Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026